Your browser doesn't support javascript.
loading
A descriptive study of commercial herbal dietary supplements used for dyslipidemia-Sales data and suspected adverse reactions.
Allkanjari, Olta; Menniti-Ippolito, Francesca; Ippoliti, Ilaria; Di Giacomo, Silvia; Piccioni, Tito; Vitalone, Annabella.
Afiliación
  • Allkanjari O; Department of Physiology and Pharmacology 'Vittorio Erspamer', Sapienza University of Rome, Rome, Italy.
  • Menniti-Ippolito F; National Centre for Drug Research and Evaluation, National Institute of Health, Rome, Italy.
  • Ippoliti I; National Centre for Drug Research and Evaluation, National Institute of Health, Rome, Italy.
  • Di Giacomo S; Department of Physiology and Pharmacology 'Vittorio Erspamer', Sapienza University of Rome, Rome, Italy.
  • Piccioni T; Farmacia Piccioni Tito, Rome, Italy.
  • Vitalone A; Department of Physiology and Pharmacology 'Vittorio Erspamer', Sapienza University of Rome, Rome, Italy.
Phytother Res ; 36(6): 2583-2604, 2022 Jun.
Article en En | MEDLINE | ID: mdl-35524700
Herbal dietary supplements (HDS) used for dyslipidemia represent a category of concern in Italy for suspected adverse reactions (ARs). However, we cannot estimate their safety, as we do not know their commercial profile. Sales data of HDS, and particularly, those used for dyslipidemia, were monitored for 2 years in two pharmacies of Rome. Meanwhile, spontaneous reports of suspected ARs potentially related to dyslipidemia supplements were collected by the Italian Phytovigilance System. The 50% of the total dietary supplements are herbal-derived; the 9% of HDS are recommended for dyslipidemia. From our data, 113 different brands have claims for improving lipids profile and 91% of them are multiingredient preparations. Fifteen spontaneous reports of suspected ARs concerned HDS used, for dyslipidemia. The most frequent ARs were joint, abdominal, and muscles pain; vomiting; erythema and hematological disorders; nausea; and rhabdomyolysis. Our findings point out the limited compliance of commercial dyslipidemia-HDS and scientific research about their intrinsic safety. A wide range of ingredients could not support the risk/benefit profile of the supplement. The variable compositions of HDS do not assure the safety, as they do not support the reproducibility of their pharmacological activities. This study could contribute to optimize consumer guidance about what they purchase and consume.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Suplementos Dietéticos / Dislipidemias Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Suplementos Dietéticos / Dislipidemias Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Phytother Res Asunto de la revista: TERAPIAS COMPLEMENTARES Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido